RNA, U6 small nuclear 678, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-678P profile across patient tissues and cancer cell-line models. RNU6-678P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNU6-678P is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, RNU6-678P RNA expression shows 14,283 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, HNSC, and THYM as cancer lineages where RNU6-678P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-678P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-678P survival associations across molecular data types. RNU6-678P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-678P RNA expression–survival associations across cancer types. High RNU6-678P expression shows unfavorable associations in LIHC, KIRC, COAD and ACC, but favorable associations in UCS and SKCM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNU6-678P RNA expression.
This table summarizes RNU6-678P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-678P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-678P shows lower tumor expression in COAD and higher tumor expression in HNSC, CHOL, LUSC, LIHC and KICH. The HNSC box plot shows higher RNU6-678P RNA expression in tumor versus normal tissue (log2 FC = +0.205, t-test p = .022).
This table shows molecular features associated with RNU6-678P in patient tissues and cancer cell lines. In patient samples, RNU6-678P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
